

Source Naturals, Inc.  
Scotts Valley, CA 95066

December 4, 2000

3288 01 MAR 16 A6 54

Office of Special Nutritionals (HFS-450)  
Center for Food Safety and Applied Nutrition  
Food and Drug Administration  
200 C St. SW.,  
Washington, D.C. 20204

JAN - 8 2001

RE: Notification of Nutritional Support Statements


Dear Sir or Madam:

I hereby notify the Food and Drug Administration (FDA) of the use of statements of nutritional support in the labeling of DLPA, a dietary supplement. Source Naturals<sup>®</sup> is the manufacturer of DLPA.

Statements being made in the labeling of DLPA:

(1) Researchers believe that D-phenylalanine (DPA) inhibits the action of an enzyme that breaks down endorphins and enkephalins. These are proteins which bind to opiate receptor sites in the brain, thereby influencing the perception of minor discomfort associated with normal physiological processes. By obstructing the action of this enzyme, DPA may extend the life of endorphins and enkephalins and their positive influence on comfort levels. L-phenylalanine is the precursor to two neurotransmitters that help support an alert state.

To the best of my knowledge, and based upon information and belief present at the time of the execution of this notice, I certify that the above information is accurate and complete. Source Naturals possesses substantiation that the statements are truthful and not misleading.

  
Ira L. Goldberg  
President, Source Naturals, Inc.

97S 0162

LET 7070

74381

12373